Ozempic, blockbuster weight-loss drug, launches in India.

• Ozempic, a once-weekly injection for type 2 diabetes by Novo Nordisk, has launched in India.
• The drug is priced at Rs. 2,200 per week, with a pen containing four doses costing Rs 8,800.
• Ozempic (semaglutide) manages blood sugar, promotes insulin production, and aids in weight loss by mimicking GLP-1 hormones.
• It can lead to 15-20% weight loss, improving metabolic health, but has common side effects like nausea and vomiting.
• India's anti-obesity drug market is rapidly growing, with Ozempic joining other GLP-1 drugs.

Why It Matters: Ozempic's arrival in India could transform diabetes and obesity treatment.